Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 15;66(2):e0166721.
doi: 10.1128/AAC.01667-21. Epub 2021 Nov 22.

Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019)

Cecilia G Carvalhaes  1 , Helio S Sader  1 , Jennifer M Streit  1 , Mariana Castanheira  1 , Rodrigo E Mendes  1
Affiliations

Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019)

Cecilia G Carvalhaes et al. Antimicrob Agents Chemother. .

Abstract

Oritavancin displayed potent and stable activity (MIC90 range of 0.06 to 0.5 mg/L) over a 10-year period (2010 to 2019) against Gram-positive pathogens that cause bloodstream infections (BSI), including methicillin-resistant Staphylococcus aureus (MRSA) and resistant subsets of Enterococcus spp. Daptomycin and linezolid were also active against methicillin-resistant S. aureus and vancomycin-resistant Enterococcus (VRE). Only oritavancin and linezolid remained active against Enterococcus faecium isolates displaying an elevated daptomycin MIC (i.e., 2 to 4 mg/L). Proportions of methicillin-resistant S. aureus and vancomycin-resistant Enterococcus within the respective S. aureus and enterococcal populations decreased over this period.

Keywords: E. faecium; VRE; VanA; VanB; daptomycin resistance; lipoglycopeptides; vancomycin resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Timbrook TT, Morton JB, McConeghy KW, Caffrey AR, Mylonakis E, LaPlante KL. 2017. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. Clin Infect Dis 64:15–23. doi: 10.1093/cid/ciw649. - DOI - PubMed
    1. Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, Jones RN. 2019. The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 63:e00355. doi: 10.1128/AAC.00355-19. - DOI - PMC - PubMed
    1. CDC. 2019. Antibiotic resistance threats in the United States, 2019. Available at https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-re.... Accessed April 2020.
    1. Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, Giordano P, Lucasti C, Perez A, Good S, Jiang H, Moeck G, O'Riordan W, Investigators SI, SOLO I Investigators. 2014. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 370:2180–2190. doi: 10.1056/NEJMoa1310422. - DOI - PubMed
    1. Mendes RE, Sader HS, Castanheira M, Flamm RK. 2018. Distribution of main Gram-positive pathogens causing bloodstream infections in the United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010–2016): concomitant analysis of oritavancin in vitro activity. J Chemother 30:280–289. doi: 10.1080/1120009X.2018.1516272. - DOI - PubMed

Publication types

MeSH terms